| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/17/2002 | WO2002003920A2 Method for treatment of reactive arthritis or bursitis |
| 01/17/2002 | WO2002003918A2 Treating neural conditions resulting from spinal cord contusions and other causes |
| 01/17/2002 | WO2002003915A2 Methods of producing weight loss and treatment of obesity |
| 01/17/2002 | WO2002003914A2 Improved thyroid hormone formulations |
| 01/17/2002 | WO2002003912A2 Novel c-4 substituted retinoids |
| 01/17/2002 | WO2002003899A1 Method and manufacture of a wound dressing for covering an open wound |
| 01/17/2002 | WO2002003896A1 Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections |
| 01/17/2002 | WO2002003886A1 Treatment of human herpesviruses using hyperthermia |
| 01/17/2002 | WO2002003815A2 Composition for the treatment of migraine |
| 01/17/2002 | WO2001081309A3 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol |
| 01/17/2002 | WO2001078693A3 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets |
| 01/17/2002 | WO2001068186A3 Use of cyanoquinolines for treating or inhibiting colonic polyps |
| 01/17/2002 | WO2001068138A3 Intradermal-penetration agents for topical local anesthetic administration |
| 01/17/2002 | WO2001068064A3 Use of cdp-choline for the prophylactic treatment of cerebral ischemia |
| 01/17/2002 | WO2001064200A3 Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy |
| 01/17/2002 | WO2001062786A3 Tlp peptides and dna sequences coding the same |
| 01/17/2002 | WO2001062726A3 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
| 01/17/2002 | WO2001060826A3 SUCCINOYLAMINO CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
| 01/17/2002 | WO2001060346A3 Nutritional formulation containing prebiotic substances |
| 01/17/2002 | WO2001059067A3 A group of anti-cancer compounds with specific structure and their production method |
| 01/17/2002 | WO2001055370A3 MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
| 01/17/2002 | WO2001054681A8 Composition for treatment of stress |
| 01/17/2002 | WO2001054678A3 Combination therapy for cancer |
| 01/17/2002 | WO2001051004A3 Anti-cancer agent containing naphthoquinone compound |
| 01/17/2002 | WO2001047950A3 Basolateral sorting signal based on scf peptide and inhibitors thereof |
| 01/17/2002 | WO2001047922A3 Azaindoles |
| 01/17/2002 | WO2001047560A3 Particulate vitamin composition |
| 01/17/2002 | WO2001047543A3 Activation and inhibition of the immune system |
| 01/17/2002 | WO2001046125A3 Cd45 inhibitors |
| 01/17/2002 | WO2001043722A3 Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces |
| 01/17/2002 | WO2001043558A3 Reduced calorie fat compositions |
| 01/17/2002 | WO2001041775A3 Use of procyanidins in the maintenance of vascular health and modulation of the inflammatory response |
| 01/17/2002 | WO2001041707A3 Modulation of in vivo glutamine and glycine levels in the treatment of autism |
| 01/17/2002 | WO2001040455A3 Compositions and methods for increasing packaging and yields of recombinant adenoviruses using multiple packaging signals |
| 01/17/2002 | WO2001040242A3 6-o-methylerythromycin a crystal form iii |
| 01/17/2002 | WO2001039760A3 Method of treating batten disease |
| 01/17/2002 | WO2001039759A3 Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds |
| 01/17/2002 | WO2001038303A3 Vitamin d analogues |
| 01/17/2002 | WO2001035948A3 Neurophilin ligands for treating ocular conditions |
| 01/17/2002 | WO2001034769A3 24 human secreted proteins |
| 01/17/2002 | WO2001034552A3 Benzenoid derivatives of 15-hydroxyeicosatetraenoic acid and methods of their use in treating dry eye disorders |
| 01/17/2002 | WO2001032830A3 Process for producing, methods and compositions of glucuronoxylomannan as nutriceutical agent from higher basidiomycetes mushroom |
| 01/17/2002 | WO2001032706A3 Novel human transporter proteins and polynucleotides encoding the same |
| 01/17/2002 | WO2001031051A3 Antisense modulation of protein kinase c-theta expression |
| 01/17/2002 | WO2001030997A3 Microbe, microbial exopolysaccharide, and uses thereof |
| 01/17/2002 | WO2001030996A3 Microbial exopolysaccharide and uses thereof |
| 01/17/2002 | WO2001030362A3 Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| 01/17/2002 | WO2001027290A3 Aortic carboxypeptidase-like protein and nucleic acids encoding same |
| 01/17/2002 | WO2001026603A3 Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives |
| 01/17/2002 | WO2001022972A3 Immunostimulatory nucleic acids |
| 01/17/2002 | WO2001021589A3 Mono- and bis-indolylquinones and prophylactic and therapeutic uses thereof |
| 01/17/2002 | WO2001021259A3 Use and compositions for treating platelet-related disorders using anagrelide |
| 01/17/2002 | WO2001021161A3 Use of desloratadine for treating allergic and inflammatory conditions |
| 01/17/2002 | WO2001019817A3 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission |
| 01/17/2002 | WO2001019407A3 Taxane prodrugs |
| 01/17/2002 | WO2001019406A3 Amphiphilic prodrugs |
| 01/17/2002 | WO2001017565A3 Polyoxyalkylenes conjugates as enzyme inhibitors |
| 01/17/2002 | WO2001016377A3 Diagnostics and therapeutics for osteoporosis |
| 01/17/2002 | WO2001013117A3 Proteins, genes and their use for diagnosis and treatment of breast cancer |
| 01/17/2002 | WO2001012171A3 Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of behavioral diseases |
| 01/17/2002 | WO2001010468A3 Drug-carrier complexes and methods of use thereof |
| 01/17/2002 | WO2001007087A3 Enzyme catalyzed anti-infective therapeutic agents |
| 01/17/2002 | WO2001007025A3 Treatment of cardiac abnormalities with aryloxy propanolamines |
| 01/17/2002 | WO2001001973A3 Highly selective norepinephrine reuptake inhibitors and methods of using the same |
| 01/17/2002 | WO2000078971A3 Atp binding cassette transporter protein abc1 popypeptides |
| 01/17/2002 | WO2000078953A3 Human transport proteins |
| 01/17/2002 | WO2000074649A3 Ophthalmic histamine compositions and uses thereof |
| 01/17/2002 | WO2000071493A3 INHIBITORS OF FACTOR Xa |
| 01/17/2002 | WO2000061129A3 S-hydroxynefazodone |
| 01/17/2002 | WO2000060077A3 Compounds for therapy and diagnosis of lung cancer and methods for their use |
| 01/17/2002 | WO2000025798A8 Treatment of parkinson's disease with oligonucleotides |
| 01/17/2002 | US20020007215 Drug/drug delivery systems for the prevention and treatment of vascular disease |
| 01/17/2002 | US20020007214 Drug/drug delivery systems for the prevention and treatment of vascular disease |
| 01/17/2002 | US20020007213 Drug/drug delivery systems for the prevention and treatment of vascular disease |
| 01/17/2002 | US20020007085 Novel intermediates useful for the preparation of antihistaminic piperidine derivatives |
| 01/17/2002 | US20020007079 Meiosis regulating compounds |
| 01/17/2002 | US20020007075 Neurological disorders including physically damaged nerves and neurodegenerative diseases, and for treating alopecia and promoting hair growth; Alzheimer's, Parkinson's disease; amyotrophic lateral sclerosis |
| 01/17/2002 | US20020007074 Imidazole derivatives having affinity for alpha2 receptors |
| 01/17/2002 | US20020007073 Capable of producing complexes with polynucleotides (DNA, RNA, antisense oligonucleotides, ribozymes); suitable as vectors for transfection |
| 01/17/2002 | US20020007071 Treating disorders which include neuropeptide Y excess; antagonists, antagonism |
| 01/17/2002 | US20020007070 For inhibiting loss of blood platelets; inhibiting formation of blood platelet aggregates, fibrin, thrombus, and embolus; anticoagulants embedded in devices for blood collection, circulation, storage (catheters, dialysis machines); stents |
| 01/17/2002 | US20020007069 Reacting 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl) methyl)thio)benzimidazole with 3-chloroperoxybenzoic acid in ethyl acetate; purifying by dissolving in methylamine and by precipitation via addition of hydrochloric acid; purity |
| 01/17/2002 | US20020007068 Piperidine derivatives and process for their production |
| 01/17/2002 | US20020007066 For treatment/prevention of infection of herpes simplex virus, varicella zoster virus, human cytomegalovirus, or epstein-Barr virus; enzyme inhibitors |
| 01/17/2002 | US20020007065 Cyclopentanone dihydropyridine compounds useful as potassium channel openers |
| 01/17/2002 | US20020007064 For prevention of psychotic disorders such as schizophrenia and other central nervous system diseases |
| 01/17/2002 | US20020007062 Enyme inhibitors for treating neurodegenerative diseases; inhibition of lipidic peroxidation and nitrogen oxide synthase in warm-blooded animal; for treatment of cardiovascular/brain disorders |
| 01/17/2002 | US20020007060 Enzyme inhibitors; connective tissue cells; antiarthritic agents; anticarcinogenic agents |
| 01/17/2002 | US20020007049 Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof |
| 01/17/2002 | US20020006967 Methods of treatment of ocular neovascularization |
| 01/17/2002 | US20020006966 Curcumin and curcuminoid inhibition of angiogenesis |
| 01/17/2002 | US20020006965 Methods and compositions for treating depression and other disorders using optically pure (-)-bupropion |
| 01/17/2002 | US20020006964 Eating disorders; psychological disorders |
| 01/17/2002 | US20020006963 Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds |
| 01/17/2002 | US20020006962 Bio-energy muscle relaxants |
| 01/17/2002 | US20020006961 Inflammation modulator, antioxidant; administering moisturizing buffered saline solution |
| 01/17/2002 | US20020006959 Therapy for reduced nervous cell metabolism |
| 01/17/2002 | US20020006957 Method for the synthesis of compounds of formula I and their uses thereof |
| 01/17/2002 | US20020006955 Ginkgolides for inhibition of membrane expression of benzodiazepine receptors |
| 01/17/2002 | US20020006954 Desmethyl tocopherols for preventing or slowing degenerative neurological diseases |